Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients

The first-line therapy in advanced kidney cancer has changed in recent years due to the introduction of combinations of tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors (ICIs). Although immune-related adverse events are well-k...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Andrea Boutros, Lara Vera, Federico Gatto, Giuseppe Fornarini, Elisa Zanardi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Subjects:	pembrolizumab axitinib kidney cancer hypothyroidism myopathy hypothyroid myopathy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1048526/full